Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma

NCT00003967 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00003967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
September 30, 1999
Completion date
Not reported
Enrollment
24 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer